Research ExplorerPublicationsE-Cadherin fragments as potential mediators for peritoneal m...

E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer

Standard

E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. / Trillsch, Fabian; Kuerti, Sascha ; zu Eulenburg, Christine; Burandt, Eike; Woelber, Linn; Prieske, Katharina; Eylmann, Kathrin; Oliveira-Ferrer, Leticia; Milde-Langosch, Karin; Mahner, Sven.

In: BRIT J CANCER, Vol. 114, No. 2, 12.01.2016, p. 213-220.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Trillsch, F, Kuerti, S, zu Eulenburg, C, Burandt, E, Woelber, L, Prieske, K, Eylmann, K, Oliveira-Ferrer, L, Milde-Langosch, K & Mahner, S 2016, 'E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer', BRIT J CANCER, vol. 114, no. 2, pp. 213-220. https://doi.org/10.1038/bjc.2015.436

APA

Trillsch, F., Kuerti, S., zu Eulenburg, C., Burandt, E., Woelber, L., Prieske, K., Eylmann, K., Oliveira-Ferrer, L., Milde-Langosch, K., & Mahner, S. (2016). E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. BRIT J CANCER, 114(2), 213-220. https://doi.org/10.1038/bjc.2015.436

Vancouver

Trillsch F, Kuerti S, zu Eulenburg C, Burandt E, Woelber L, Prieske K et al. E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. BRIT J CANCER. 2016 Jan 12;114(2):213-220. https://doi.org/10.1038/bjc.2015.436

Bibtex

@article{dec8178df16348ea8f004b676d73ceb1,
title = "E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer",
abstract = "BACKGROUND: Peritoneal dissemination and retroperitoneal lymph node involvement are main routes for tumour spread of epithelial ovarian cancer (EOC), possibly determined by the intercellular connecting protein E-Cadherin (E-Cad) and its fragments.METHODS: Tumour tissue of 105 advanced EOC patients was evaluated for protein expression of E-Cad, β-Catenin and Calpain by western blotting and immunohistochemistry. Expression patterns were compared between tumours with solely intraperitoneal (pT3c, pN0; n=41) and tumours with retroperitoneal metastases (pT1a-3c, pN1; n=64). Lysates of the EOC cell line SKOV3 and tumour tissue from the intraperitoneal group were tested for E-Cad expression following Calpain treatment.RESULTS: E-Cad full-length (E-Cad-FL, 120 kDa) and two major fragments at 85 kDa (E-Cad-85) and 23 kDa (E-Cad-23) were detected by western blotting. E-Cad-85 expression was significantly higher in tumours with solely intraperitoneal metastases and correlated strongly with E-Cad-23 and the protease Calpain. Calpain-mediated cleavage was identified as a potential mechanism to generate E-Cad-85 from E-Cad-FL by treating lysates from SKOV3 cells and tumour tissue with this enzyme. Increased cytoplasmic localisation of β-Catenin in tumours with high E-Cad-85 expression corroborates that E-Cad-85 loses the binding site for β-Catenin after fragmentation, enabling tumour cluster formation and peritoneal dissemination.CONCLUSIONS: Calpain-mediated E-Cad fragmentation appears to promote intraperitoneal EOC progression. Understanding these mechanisms might eventually lead to new tailored subtype-specific diagnostic and therapeutic interventions.British Journal of Cancer advance online publication 12 January 2016. doi:10.1038/bjc.2015.436 www.bjcancer.com.",
author = "Fabian Trillsch and Sascha Kuerti and {zu Eulenburg}, Christine and Eike Burandt and Linn Woelber and Katharina Prieske and Kathrin Eylmann and Leticia Oliveira-Ferrer and Karin Milde-Langosch and Sven Mahner",
year = "2016",
month = jan,
day = "12",
doi = "10.1038/bjc.2015.436",
language = "English",
volume = "114",
pages = "213--220",
journal = "BRIT J CANCER",
issn = "0007-0920",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer

AU - Trillsch, Fabian

AU - Kuerti, Sascha

AU - zu Eulenburg, Christine

AU - Burandt, Eike

AU - Woelber, Linn

AU - Prieske, Katharina

AU - Eylmann, Kathrin

AU - Oliveira-Ferrer, Leticia

AU - Milde-Langosch, Karin

AU - Mahner, Sven

PY - 2016/1/12

Y1 - 2016/1/12

N2 - BACKGROUND: Peritoneal dissemination and retroperitoneal lymph node involvement are main routes for tumour spread of epithelial ovarian cancer (EOC), possibly determined by the intercellular connecting protein E-Cadherin (E-Cad) and its fragments.METHODS: Tumour tissue of 105 advanced EOC patients was evaluated for protein expression of E-Cad, β-Catenin and Calpain by western blotting and immunohistochemistry. Expression patterns were compared between tumours with solely intraperitoneal (pT3c, pN0; n=41) and tumours with retroperitoneal metastases (pT1a-3c, pN1; n=64). Lysates of the EOC cell line SKOV3 and tumour tissue from the intraperitoneal group were tested for E-Cad expression following Calpain treatment.RESULTS: E-Cad full-length (E-Cad-FL, 120 kDa) and two major fragments at 85 kDa (E-Cad-85) and 23 kDa (E-Cad-23) were detected by western blotting. E-Cad-85 expression was significantly higher in tumours with solely intraperitoneal metastases and correlated strongly with E-Cad-23 and the protease Calpain. Calpain-mediated cleavage was identified as a potential mechanism to generate E-Cad-85 from E-Cad-FL by treating lysates from SKOV3 cells and tumour tissue with this enzyme. Increased cytoplasmic localisation of β-Catenin in tumours with high E-Cad-85 expression corroborates that E-Cad-85 loses the binding site for β-Catenin after fragmentation, enabling tumour cluster formation and peritoneal dissemination.CONCLUSIONS: Calpain-mediated E-Cad fragmentation appears to promote intraperitoneal EOC progression. Understanding these mechanisms might eventually lead to new tailored subtype-specific diagnostic and therapeutic interventions.British Journal of Cancer advance online publication 12 January 2016. doi:10.1038/bjc.2015.436 www.bjcancer.com.

AB - BACKGROUND: Peritoneal dissemination and retroperitoneal lymph node involvement are main routes for tumour spread of epithelial ovarian cancer (EOC), possibly determined by the intercellular connecting protein E-Cadherin (E-Cad) and its fragments.METHODS: Tumour tissue of 105 advanced EOC patients was evaluated for protein expression of E-Cad, β-Catenin and Calpain by western blotting and immunohistochemistry. Expression patterns were compared between tumours with solely intraperitoneal (pT3c, pN0; n=41) and tumours with retroperitoneal metastases (pT1a-3c, pN1; n=64). Lysates of the EOC cell line SKOV3 and tumour tissue from the intraperitoneal group were tested for E-Cad expression following Calpain treatment.RESULTS: E-Cad full-length (E-Cad-FL, 120 kDa) and two major fragments at 85 kDa (E-Cad-85) and 23 kDa (E-Cad-23) were detected by western blotting. E-Cad-85 expression was significantly higher in tumours with solely intraperitoneal metastases and correlated strongly with E-Cad-23 and the protease Calpain. Calpain-mediated cleavage was identified as a potential mechanism to generate E-Cad-85 from E-Cad-FL by treating lysates from SKOV3 cells and tumour tissue with this enzyme. Increased cytoplasmic localisation of β-Catenin in tumours with high E-Cad-85 expression corroborates that E-Cad-85 loses the binding site for β-Catenin after fragmentation, enabling tumour cluster formation and peritoneal dissemination.CONCLUSIONS: Calpain-mediated E-Cad fragmentation appears to promote intraperitoneal EOC progression. Understanding these mechanisms might eventually lead to new tailored subtype-specific diagnostic and therapeutic interventions.British Journal of Cancer advance online publication 12 January 2016. doi:10.1038/bjc.2015.436 www.bjcancer.com.

U2 - 10.1038/bjc.2015.436

DO - 10.1038/bjc.2015.436

M3 - SCORING: Journal article

C2 - 26757261

VL - 114

SP - 213

EP - 220

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 2

ER -